The IAP antagonist birinapant enhances chimeric antigen receptor T cell therapy for glioblastoma by overcoming antigen heterogeneity
Antigen heterogeneity that results in tumor antigenic escape is one of the major obstacles to successful chimeric antigen receptor (CAR) T cell therapies in solid tumors including glioblastoma multiforme (GBM). To address this issue and improve the efficacy of CAR T cell therapy for GBM, we develope...
Main Authors: | Edward Z. Song, Xin Wang, Benjamin I. Philipson, Qian Zhang, Radhika Thokala, Logan Zhang, Charles-Antoine Assenmacher, Zev A. Binder, Guo-li Ming, Donald M. O’Rourke, Hongjun Song, Michael C. Milone |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2022-12-01
|
Series: | Molecular Therapy: Oncolytics |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2372770522001395 |
Similar Items
-
The expanding role of IAP antagonists for the treatment of head and neck cancer
by: Vikash Kansal, et al.
Published: (2023-07-01) -
Birinapant Reshapes the Tumor Immunopeptidome and Enhances Antigen Presentation
by: Weiyan Zhang, et al.
Published: (2024-03-01) -
An Updated Review of Smac Mimetics, LCL161, Birinapant, and GDC-0152 in Cancer Treatment
by: Yung-Chieh Chang, et al.
Published: (2020-12-01) -
Combinatorial Treatment of Birinapant and Zosuquidar Enhances Effective Control of HBV Replication In Vivo
by: Emma Morrish, et al.
Published: (2020-08-01) -
Regulation of Apoptosis by Inhibitors of Apoptosis (IAPs)
by: Laurence Dubrez, et al.
Published: (2013-03-01)